Quest Diagnostics (DGX) Stock Forecast & Price Target

Compare

951 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DGX Analyst Ratings

Moderate Buy

5 Buy

6 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Quest

Diagnostics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DGX Stock 12 Month Forecast

Average Price Target

$188.60

▲(8.22% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Quest Diagnostics in the last 3 months. The average price target is $188.60 with a high forecast of $198.00 and a low forecast of $178.00. The average price target represents a 8.22% change from the last price of $174.27.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"132":"$132","199":"$199","148.75":"$148.8","165.5":"$165.5","182.25":"$182.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":198,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$198.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":188.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$188.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":178,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$178.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[132,148.75,165.5,182.25,199],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,178.52,180.01846153846154,181.5169230769231,183.01538461538462,184.51384615384617,186.0123076923077,187.51076923076923,189.00923076923078,190.5076923076923,192.00615384615384,193.5046153846154,195.00307692307692,196.50153846153847,{"y":198,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,178.52,179.29538461538462,180.07076923076923,180.84615384615384,181.62153846153848,182.3969230769231,183.1723076923077,183.9476923076923,184.72307692307692,185.49846153846153,186.27384615384616,187.04923076923077,187.82461538461538,{"y":188.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,178.52,178.48000000000002,178.44,178.4,178.36,178.32,178.28,178.24,178.20000000000002,178.16,178.12,178.08,178.04,{"y":178,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":133.76,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.86,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.08,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.72,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.57,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.69,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$198.00

Average Price Target$188.60

Lowest Price Target$178.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$188

Hold

7.88%

Upside

Downgraded

08/02/25

Quest Diagnostics receives a strong overall score driven by solid financial performance and positive earnings call sentiment. The company exhibits healthy profitability and cash flow, boosted by successful acquisitions and operational improvements. However, mixed revenue growth and moderate technical indicators slightly temper the outlook.

David WestenbergPiper Sandler

Piper Sandler

$190

Hold

9.03%

Upside

Reiterated

07/28/25

Piper Sandler Sticks to Their Hold Rating for Quest Diagnostics (DGX)

David S MacdonaldTruist Financial

Truist Financial

$190→$192

Hold

10.17%

Upside

Reiterated

07/23/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Intuitive Surgical (NASDAQ: ISRG), Quest Diagnostics (NYSE: DGX) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Pito ChickeringDeutsche Bank

Deutsche Bank

$160→$178

Hold

2.14%

Upside

Reiterated

07/23/25

Quest Diagnostics price target raised to $178 from $160 at Deutsche BankQuest Diagnostics price target raised to $178 from $160 at Deutsche Bank

Kevin CaliendoUBS

UBS

$175→$180

Hold

3.29%

Upside

Reiterated

07/23/25

Quest Diagnostics price target raised to $180 from $175 at UBSQuest Diagnostics price target raised to $180 from $175 at UBS

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$180→$185

Hold

6.16%

Upside

Reiterated

07/23/25

Quest Diagnostics price target raised to $185 from $180 at Evercore ISIQuest Diagnostics price target raised to $185 from $180 at Evercore ISI

Luke SergottBarclays

Barclays

$185

Hold

6.16%

Upside

Reiterated

07/23/25

Barclays Reaffirms Their Hold Rating on Quest Diagnostics (DGX)

Erin WrightMorgan Stanley

Morgan Stanley

$182→$191

Buy

9.60%

Upside

Reiterated

07/22/25

Quest Diagnostics: Strong Financial Outlook and Strategic Positioning Justify Buy Rating

Michael ChernyLeerink Partners

Leerink Partners

$192

Buy

10.17%

Upside

Reiterated

07/22/25

Quest Diagnostics: Strong Volume Growth and Strategic Partnerships Drive Buy RatingWe also viewed management's commentary around potential macro changes tied to eroding Medicaid/HIX volumes as encouraging and providing an appropriate baseline when thinking through FY26/FY27 potential headwinds. PAMA remains a wildcard and would be a real impact of up to $100MM of price if it is not delayed a year. But if it were to happen - it's a one-time reboot/rebase that DGX could grow back off of. We continue to like DGX's high degree of visibility on steady earnings growth and investments into driving better growth both in the medium and longer term. We reiterate our Outperform rating $192 price target (~18x CY26 P/E) as we view this visibility as warranting a robust multiple.

Andrew BrackmannWilliam Blair

William Blair

―

Buy

―

Reiterated

07/22/25

Quest Diagnostics' Strong Q2 Performance and Upgraded Guidance Reinforce Buy RatingWe believe the durability of this growth rate will be a key focus on the call, as it could further command a premium multiple versus the historical rate, in our view. On the profitability front, adjusted operating margins are still expected to increase over the prior year and adjusted EPS were increased by $0.05 at the midpoint to $9.73.

Michael RyskinBank of America Securities

Bank of America Securities

$198

Buy

13.62%

Upside

Reiterated

07/22/25

Quest Diagnostics: Strong Performance and Growth Potential Justify Buy Rating

Tycho PetersonJefferies

Jefferies

$195

Buy

11.90%

Upside

Reiterated

06/11/25

Quest Diagnostics: Strategic Positioning and Growth Potential Amid Reimbursement Challenges

Lisa GillJ.P. Morgan

J.P. Morgan

$180→$190

Hold

9.03%

Upside

Reiterated

05/06/25

Analysts Conflicted on These Healthcare Names: Biomea Fusion (NASDAQ: BMEA) and Quest Diagnostics (NYSE: DGX)

Patrick B DonnellyCiti

Citi

$185

Hold

6.16%

Upside

Reiterated

05/06/25

Quest Diagnostics: Balancing Strong Q1 Performance with Moderate Future Growth Outlook

Eric ColdwellRobert W. Baird

Robert W. Baird

$191→$194

Buy

11.32%

Upside

Reiterated

04/23/25

Quest Diagnostics price target raised to $194 from $191 at BairdQuest Diagnostics price target raised to $194 from $191 at Baird

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$188

Hold

7.88%

Upside

Downgraded

08/02/25

David WestenbergPiper Sandler

Piper Sandler

$190

Hold

9.03%

Upside

Reiterated

07/28/25

Piper Sandler Sticks to Their Hold Rating for Quest Diagnostics (DGX)

David S MacdonaldTruist Financial

Truist Financial

$190→$192

Hold

10.17%

Upside

Reiterated

07/23/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Intuitive Surgical (NASDAQ: ISRG), Quest Diagnostics (NYSE: DGX) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Pito ChickeringDeutsche Bank

Deutsche Bank

$160→$178

Hold

2.14%

Upside

Reiterated

07/23/25

Quest Diagnostics price target raised to $178 from $160 at Deutsche BankQuest Diagnostics price target raised to $178 from $160 at Deutsche Bank

Kevin CaliendoUBS

UBS

$175→$180

Hold

3.29%

Upside

Reiterated

07/23/25

Quest Diagnostics price target raised to $180 from $175 at UBSQuest Diagnostics price target raised to $180 from $175 at UBS

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$180→$185

Hold

6.16%

Upside

Reiterated

07/23/25

Quest Diagnostics price target raised to $185 from $180 at Evercore ISIQuest Diagnostics price target raised to $185 from $180 at Evercore ISI

Luke SergottBarclays

Barclays

$185

Hold

6.16%

Upside

Reiterated

07/23/25

Barclays Reaffirms Their Hold Rating on Quest Diagnostics (DGX)

Erin WrightMorgan Stanley

Morgan Stanley

$182→$191

Buy

9.60%

Upside

Reiterated

07/22/25

Quest Diagnostics: Strong Financial Outlook and Strategic Positioning Justify Buy Rating

Michael ChernyLeerink Partners

Leerink Partners

$192

Buy

10.17%

Upside

Reiterated

07/22/25

Andrew BrackmannWilliam Blair

William Blair

―

Buy

―

Reiterated

07/22/25

Michael RyskinBank of America Securities

Bank of America Securities

$198

Buy

13.62%

Upside

Reiterated

07/22/25

Quest Diagnostics: Strong Performance and Growth Potential Justify Buy Rating

Tycho PetersonJefferies

Jefferies

$195

Buy

11.90%

Upside

Reiterated

06/11/25

Quest Diagnostics: Strategic Positioning and Growth Potential Amid Reimbursement Challenges

Lisa GillJ.P. Morgan

J.P. Morgan

$180→$190

Hold

9.03%

Upside

Reiterated

05/06/25

Analysts Conflicted on These Healthcare Names: Biomea Fusion (NASDAQ: BMEA) and Quest Diagnostics (NYSE: DGX)

Patrick B DonnellyCiti

Citi

$185

Hold

6.16%

Upside

Reiterated

05/06/25

Quest Diagnostics: Balancing Strong Q1 Performance with Moderate Future Growth Outlook

Eric ColdwellRobert W. Baird

Robert W. Baird

$191→$194

Buy

11.32%

Upside

Reiterated

04/23/25

Quest Diagnostics price target raised to $194 from $191 at BairdQuest Diagnostics price target raised to $194 from $191 at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Quest Diagnostics

1 Month

xxx

Success Rate

5/9 ratings generated profit

Average Return

+0.94%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +0.94% per trade.

3 Months

xxx

Success Rate

6/9 ratings generated profit

Average Return

+3.70%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.70% per trade.

1 Year

Eric ColdwellRobert W. Baird

Success Rate

14/17 ratings generated profit

Average Return

+10.08%

reiterated a buy rating 4 months ago

Copying Eric Coldwell's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +10.08% per trade.

2 Years

xxx

Success Rate

16/17 ratings generated profit

Average Return

+15.99%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +15.99% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DGX Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DGX has received 15 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. DGX average Analyst price target in the past 3 months is 188.60.

Each month's total comprises the sum of three months' worth of ratings.

DGX Financial Forecast

DGX Earnings Forecast

Next quarter’s earnings estimate for DGX is $2.50 with a range of $2.46 to $2.57. The previous quarter’s EPS was $2.62. DGX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.44% of the time in the same period. In the last calendar year DGX has Outperformed its overall industry.

DGX Sales Forecast

Next quarter’s sales forecast for DGX is $2.73B with a range of $2.71B to $2.77B. The previous quarter’s sales results were $2.76B. DGX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.90% of the time in the same period. In the last calendar year DGX has Outperformed its overall industry.

DGX Stock Forecast FAQ

What is DGX’s average 12-month price target, according to analysts?

Based on analyst ratings, Quest Diagnostics’s 12-month average price target is 188.60.

What is DGX’s upside potential, based on the analysts’ average price target?

Quest Diagnostics has 8.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DGX a Buy, Sell or Hold?

Quest Diagnostics has a consensus rating of Moderate Buy which is based on 5 buy ratings, 6 hold ratings and 0 sell ratings.

What is Quest Diagnostics’s price target?

The average price target for Quest Diagnostics is 188.60. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $198.00 ,the lowest forecast is $178.00. The average price target represents 8.22% Increase from the current price of $174.27.

What do analysts say about Quest Diagnostics?

Quest Diagnostics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of DGX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Quest Diagnostics (DGX) Stock Forecast & Price Target

DGX Analyst Ratings

DGX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Quest Diagnostics

DGX Analyst Recommendation Trends

DGX Financial Forecast

DGX Earnings Forecast

DGX Sales Forecast

DGX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts